AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for DnaJ homolog subfamily B member 6

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

O75190

UPID:

DNJB6_HUMAN

Alternative names:

HHDJ1; Heat shock protein J2; MRJ; MSJ-1

Alternative UPACC:

O75190; A4D232; A8K7D8; A8KAG0; B4DN73; E9PCZ2; O95806; Q53EN8; Q59EF2; Q6FIC8; Q75MA2; Q9UIK6

Background:

DnaJ homolog subfamily B member 6, known by alternative names such as HHDJ1, Heat shock protein J2, MRJ, and MSJ-1, plays a crucial role in cellular processes. It enhances the ATPase activity of HSP70, acting as a co-chaperone. This protein is vital in organizing KRT8/KRT18 filaments and serves as a molecular chaperone for neuronal proteins, including huntingtin, reducing aggregation and toxicity of polyglutamine-containing proteins.

Therapeutic significance:

Linked to Muscular dystrophy, limb-girdle, autosomal dominant 1, DnaJ homolog subfamily B member 6's dysfunction, particularly isoform B, is implicated in disease pathogenesis. Understanding its role could lead to novel therapeutic strategies for this and related myopathies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.